Table 2.

Comparison of clinical trial patients included or not included in the EBV study. Interquartile range (IQR).

	In EBV Study (n = 189)	Not in EBV Study (n = 198)	p-Value
Age at diagnosis			0.9
Median, IQR	13.32 (10.25–14.86)	13.20 (10.00–14.69)
Gender			0.9
Male	119 (65.0%)	116 (58.5%)
Female	64 (35.0%)	82 (41.5%)
Subtype			0.8
Nodular sclerosing	126 (75.9%)	129 (65.1%)
Mixed cellularity	26 (15.6%)	39 (19.6%)
Other/unknown	14 (8.4%)	30 (15.1%)
Stage			0.2
I	23 (12.5%)	31 (15.6%)
II	77 (44.8%)	103 (52.0%)
III	38 (22.4%)	32 (16.1%)
IV	37 (20.2%)	32 (16.1%)
Symptoms			0.9
A	98 (59.0%)	114 (57.5%)
B	68 (41.0%)	84 (42.4%)